Update shared on16 Aug 2025
Fair value Decreased 11%The consensus Analyst Price Target for STRATA Skin Sciences has been revised downward, primarily reflecting a notable decline in the Future P/E multiple, resulting in a reduction of fair value from $9.00 to $8.00.
What's in the News
- STRATA Skin Sciences is collaborating with CMS to secure temporary reimbursement codes for its XTRAC excimer laser treatment, aiming to accelerate access to newly expanded reimbursement indications as early as the 2026 rule cycle.
- The American Medical Association's CPT Editorial Panel approved expanding reimbursement eligibility for excimer laser treatments to cover all inflammatory and autoimmune skin conditions, including vitiligo, atopic dermatitis, and alopecia areata, effective January 1, 2027.
- The expansion of covered indications could potentially triple STRATA's addressable patient population and improve treatment economics for the company and providers.
- Two new clinical studies confirmed the safety and efficacy of combining 308-nm excimer laser therapy with JAK inhibitors for vitiligo, reporting high response and stability rates with no serious adverse events.
- The revised CPT codes are expected to reduce systemic insurance denials and prior authorization requirements, further broadening access for patients with non-psoriasis conditions.
Valuation Changes
Summary of Valuation Changes for STRATA Skin Sciences
- The Consensus Analyst Price Target has significantly fallen from $9.00 to $8.00.
- The Future P/E for STRATA Skin Sciences has significantly fallen from 10.87x to 9.72x.
- The Discount Rate for STRATA Skin Sciences remained effectively unchanged, moving only marginally from 12.21% to 12.32%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.